Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer

Figure 5

BC organoids allow in vitro drug screening (a) Bar graphs displaying the IC50 values of needle biopsy sample-derived organoids treated with paclitaxel, carboplatin, neratinib, and lapatinib; b) a representative image of dose response curves for surgery sample-derived organoids treated with trastuzumab, docetaxel, tamoxifen, BYL719, and olaparib. The error bars indicate the standard error of the mean for two to three separate experiments. (c) Scatter plot displaying the distribution of IC50 values of the medications in 8 organoids, with the patient's IC50 values shown in black.

(a)

(b)

(c)